RxDoctor Payments Data

Nnamdi Nwaohiri, MD

Nephrology · Lawrenceville, GANPI 1467615120

Payments from drug & device makers

$10,572in general payments, 2019–2025

Across 243 payments — averaging $43.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • Vantive US Healthcare LLC$1K
  • Bayer$545
  • Aurinia Pharma U.S., Inc.$321
  • AstraZeneca$320
  • Calliditas Therapeutics US Inc.$247
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$1,47614%
  • Speaking & faculty fees$2,92528%
  • Travel & lodging$1,0039%
  • Food & beverage$4,79645%
  • Education$3724%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,572 in reported general payments places this provider in the 80th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$200,316
Medicare patients
215
Services billed
1,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol65$60,922
JardianceEmpagliflozin43$53,562
VelphoroSucroferric Oxyhydroxide22$48,853
LokelmaSodium Zirconium Cyclosilicate28$31,332
KerendiaFinerenone16$27,966
VeltassaPatiromer Calcium Sorbitex13$17,917
ProsolParenteral Amino Acid 20% No.150$6,248
Sevelamer Carbonate27$3,019
Diltiazem 12hr ErDiltiazem Hcl15$2,455
Midodrine Hcl28$1,640
Hydralazine Hcl74$1,634
Amlodipine Besylate281$1,362
Potassium Chloride36$1,207
Torsemide42$984
Nifedipine ErNifedipine38$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$320$92,25493 claims
Boehringer IngelheimJardiance$43$53,56243 claims
Fresenius USA Marketing, Inc.Velphoro$177$48,85322 claims
BayerKerendia$545$27,96616 claims
ANI Pharmaceuticals, Inc.Valsartan$16$54321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 nephrology providers in Georgia.

Other nephrology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →